NORWOOD, MA–(Marketwired – Aug 19, 2015) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Marketwiredhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngMarketwired2015-08-19 04:35:002015-08-19 22:13:55Corbus Pharmaceuticals’ Investigational Drug Resunab Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis